Edition:
India

Biogen Reports Top-Line Results From Phase 2 Study In Progressive Supranuclear Palsy


Friday, 13 Dec 2019 

Dec 13 (Reuters) - Biogen Inc ::BIOGEN REPORTS TOP-LINE RESULTS FROM PHASE 2 STUDY IN PROGRESSIVE SUPRANUCLEAR PALSY.BIOGEN INC - PRIMARY ENDPOINT OF PHASE 2 PASSPORT STUDY WAS NOT MET.BIOGEN INC - FURTHER DEVELOPMENT OF GOSURANEMAB IN PROGRESSIVE SUPRANUCLEAR PALSY (PSP) WILL NOT BE PURSUED.BIOGEN - TO CONTINUE ONGOING PHASE 2 TANGO STUDY OF GOSURANEMAB FOR MILD COGNITIVE IMPAIRMENT DUE TO AD , GIVEN DIFFERENCES IN DISEASE PATHOLOGY.BIOGEN INC - PRIMARY ENDPOINT, AS MEASURED BY PSP RATING SCALE (PSPRS) AT WEEK 52, WAS NOT STATISTICALLY SIGNIFICANT.BIOGEN INC - PHASE 2 STUDY IN PROGRESSIVE SUPRANUCLEAR PALSY DID NOT DEMONSTRATE EFFICACY ON KEY CLINICAL SECONDARY ENDPOINTS FROM.